1. Shizukaol D exerts a growth inhibition effect on liver cancer cells in a dose- and time-dependent manner by modulating wnt signalling pathway.
2. Shizukaol D induces mitochondrial dysfunction by depolarizing the mitochondrial membrane and suppressing energy production, which may result in AMPK activation, suggests that shizukaol D may be used to treat metabolic syndrome.
1. Asperuloside(ASP) exerts its anti-inflammatory effect in correlation with inhibition of a pro-inflammatory mediator through suppressing nuclear factor kappa-B (NF-κB) nuclear translocation and MAPK phosphorylation in a dose-dependent manner.
2. Chronic administration of Asperuloside stimulates anti-obesity and anti-metabolic syndrome activity in HFD-fed rats across several organs, similar to Eucommia leaf extract (ELE) administration, thus, ASP may be an important ingredient of ELE.
1. Norlichexanthone has the potential to treat and/or prevent lifestyle-related diseases, including metabolic syndrome, type 2 diabetes, atherosclerosis and cardiovascular diseases.
1. Anhydroicaritin exhibits immunosuppressive effect on the mouse macrophages stimulated by LPS.
2. Anhydroicaritin phytosomes can inhibit enhanced bone turnover induced by ovariectomy, improve BMD the biomechanical properties of vertebrae, without any stimulation on uterus.
3. Anhydroicaritin possesses significant protective effects on the zymosan-induced peritonitis mice, which might be associated with the regulation of Ca(2+); influx in macrophages and iNOS expression.
1. Mangiferin regulates proliferation and apoptosis in glioma cells by induction of miR-15b and inhibition of MMP-9 expression.
2. Mangiferin inhibits cell cycle progression through the ATR-Chk1 stress response DNA damage pathway, leading to cell cycle arrest at G2/M phase in leukemia cells.
3. Mangiferin has beneficial effect on the regulation of endothelial homeostasis and could be used in the management of diabetic cardiovascular complications.
4. Mangiferin prevents the renal glomerulus fibrosis of diabetic rats, through the suppression of osteopontin overproduction and inflammation likely via inactivation of NF-кB.
5. Mangiferin has anti-steatotic effect may occur independently of the hepatic signals associated with de novo fatty acid synthesis and oxidation, can inhibit hepatic DGAT-2 that catalyzes the final step in triglyceride biosynthesis .